Jeremy Grantham's UTHR Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 618 shares of United Therapeutics Corporation (UTHR) worth $301,121, representing 0.00% of the portfolio. First purchased in 2017-Q1, this long-term strategic position has been held for 25 quarters.
Based on 13F filings, Jeremy Grantham has maintained a strategic position in UTHR, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2020, adding 34,007 shares. Largest reduction occurred in Q4 2020, reducing 24,700 shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's United Therapeutics Corporation (UTHR) Holding Value Over Time
Track share changes against reported price movement
Quarterly United Therapeutics Corporation (UTHR) Trades by Jeremy Grantham
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -14,450 | Reduce 95.90% | 618 | $487.25 |
| Q3 2025 | +6,079 | Add 67.63% | 15,068 | $419.21 |
| Q2 2025 | +6,467 | Add 256.42% | 8,989 | $287.35 |
| Q1 2025 | -5,705 | Reduce 69.34% | 2,522 | $308.27 |
| Q4 2024 | +4,139 | Add 101.25% | 8,227 | $352.84 |
| Q3 2024 | -24,634 | Reduce 85.77% | 4,088 | $358.35 |
| Q2 2024 | +21,486 | Add 296.93% | 28,722 | $318.55 |
| Q1 2024 | +7,236 | New Buy | 7,236 | $229.72 |
| Q3 2021 | -2,068 | Sold Out | 0 | $0.00 |
| Q2 2021 | -4,039 | Reduce 66.14% | 2,068 | $179.40 |
| Q1 2021 | -9,100 | Reduce 59.84% | 6,107 | $167.35 |
| Q4 2020 | -24,700 | Reduce 61.89% | 15,207 | $151.77 |
| Q3 2020 | +34,007 | Add 576.39% | 39,907 | $101.01 |
| Q2 2020 | -2,400 | Reduce 28.92% | 5,900 | $121.02 |
| Q1 2020 | +8,300 | New Buy | 8,300 | $94.82 |
| Q2 2019 | -5,700 | Sold Out | 0 | $0.00 |
| Q1 2019 | -500 | Reduce 8.06% | 5,700 | $117.37 |
| Q2 2018 | +200 | Add 3.33% | 6,200 | $113.23 |
| Q1 2018 | +3,600 | Add 150.00% | 6,000 | $112.33 |
| Q2 2017 | +900 | Add 60.00% | 2,400 | $129.58 |
| Q1 2017 | +1,500 | New Buy | 1,500 | $135.33 |
Jeremy Grantham's United Therapeutics Corporation Investment FAQs
Jeremy Grantham first purchased United Therapeutics Corporation (UTHR) in Q1 2017, acquiring 1,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held United Therapeutics Corporation (UTHR) for 25 quarters since Q1 2017.
Jeremy Grantham's largest addition to United Therapeutics Corporation (UTHR) was in Q3 2020, adding 39,907 shares worth $4.03 M.
According to the latest 13F filing for Q4 2025, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 618 shares of United Therapeutics Corporation (UTHR), valued at approximately $301,121.
As of the Q4 2025 filing, United Therapeutics Corporation (UTHR) represents approximately 0.00% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings.
Jeremy Grantham's peak holding in United Therapeutics Corporation (UTHR) was 39,907 shares, as reported at the end of Q3 2020.